Jubilant Ingrevia shares are recovering after a period of decline. Domestic operations and limited US exposure shield it from tariffs. EU’s anti-dumping duty on Chinese choline chloride benefits the company. Capacity expansion and agriculture sector opportunities drive growth. Cost optimization measures are expected to improve margins. The company anticipates higher choline chloride exports to Europe.